NEW YORK (GenomeWeb News) – Illumina today said that its board of directors has authorized the repurchase of up to $100 million of the firm's outstanding common stock.

Illumina said that the shares may be purchased either on the open market or under a 10b5-1 trading program, which enables the company to purchase its shares at times when it otherwise might be prevented from doing so under insider trading laws or self-imposed trading blackout periods. The firm said that purchases will be funded through its existing cash balances.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.